Abstract
Objective There is little information regarding the incidence of bacterial infections as an adverse effect of telaprevir (TVR)-based triple therapy. This study was performed in order to evaluate the baseline and ontreatment predictors of bacterial infections in patients treated with TVR-based triple therapy. Methods This multicenter study evaluated 430 patients with chronic hepatitis C who received 12 weeks of TVR in combination with 24 weeks of pegylated interferon α2b plus ribavirin. The occurrence of a bacterial infection during anti-viral treatment was defined as the onset of local or systemic inflammation as a result of pathogenic bacteria. Results Bacterial infections occurred in 21 of the 430 (4.9%) patients during TVR-based triple therapy. Among these subjects, 71.4% (15 of 21) experienced bacterial infections during the initial eight weeks of treatment. Urinary tract infections were the most frequent infection, observed in 2.8% of cases (12 of 430). The rate of urinary tract infection among women (11 of 215, 5.1%) was significantly higher than that observed among men (1 of 215, 0.5%) (p<0.0001). According to a multivariable logistic regression analysis, the only significant independent predictor was the pretreatment serum albumin level (p=0.0008). Of the 21 patients who experienced bacterial infections, only one (4.8%) had to discontinue the treatment; however, the others were able to continue anti-viral treatment in combination with antibiotic treatment. Conclusion Clinicians should be concerned regarding the incidence of bacterial infections among patients treated with TVR-based triple therapy, especially those with a low serum albumin level.
| Original language | English |
|---|---|
| Pages (from-to) | 567-572 |
| Number of pages | 6 |
| Journal | Internal Medicine |
| Volume | 54 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Jan 1 2015 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Internal Medicine
Cite this
Bacterial infection as an adverse effect of telaprevir-based triple therapy for chronic hepatitis C infection. / Kyushu University Liver Disease Study (KULDS) Group.
In: Internal Medicine, Vol. 54, No. 6, 01.01.2015, p. 567-572.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Bacterial infection as an adverse effect of telaprevir-based triple therapy for chronic hepatitis C infection
AU - Kyushu University Liver Disease Study (KULDS) Group
AU - Kawano, Akira
AU - Ogawa, Eiichi
AU - Furusyo, Norihiro
AU - Nakamuta, Makoto
AU - Kajiwara, Eiji
AU - Dohmen, Kazufumi
AU - Nomura, Hideyuki
AU - Takahashi, Kazuhiro
AU - Satoh, Takeaki
AU - Azuma, Koichi
AU - Tanabe, Yuichi
AU - Shimoda, Shinji
AU - Kotoh, Kazuhiro
AU - Hayashi, Jun
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Objective There is little information regarding the incidence of bacterial infections as an adverse effect of telaprevir (TVR)-based triple therapy. This study was performed in order to evaluate the baseline and ontreatment predictors of bacterial infections in patients treated with TVR-based triple therapy. Methods This multicenter study evaluated 430 patients with chronic hepatitis C who received 12 weeks of TVR in combination with 24 weeks of pegylated interferon α2b plus ribavirin. The occurrence of a bacterial infection during anti-viral treatment was defined as the onset of local or systemic inflammation as a result of pathogenic bacteria. Results Bacterial infections occurred in 21 of the 430 (4.9%) patients during TVR-based triple therapy. Among these subjects, 71.4% (15 of 21) experienced bacterial infections during the initial eight weeks of treatment. Urinary tract infections were the most frequent infection, observed in 2.8% of cases (12 of 430). The rate of urinary tract infection among women (11 of 215, 5.1%) was significantly higher than that observed among men (1 of 215, 0.5%) (p<0.0001). According to a multivariable logistic regression analysis, the only significant independent predictor was the pretreatment serum albumin level (p=0.0008). Of the 21 patients who experienced bacterial infections, only one (4.8%) had to discontinue the treatment; however, the others were able to continue anti-viral treatment in combination with antibiotic treatment. Conclusion Clinicians should be concerned regarding the incidence of bacterial infections among patients treated with TVR-based triple therapy, especially those with a low serum albumin level.
AB - Objective There is little information regarding the incidence of bacterial infections as an adverse effect of telaprevir (TVR)-based triple therapy. This study was performed in order to evaluate the baseline and ontreatment predictors of bacterial infections in patients treated with TVR-based triple therapy. Methods This multicenter study evaluated 430 patients with chronic hepatitis C who received 12 weeks of TVR in combination with 24 weeks of pegylated interferon α2b plus ribavirin. The occurrence of a bacterial infection during anti-viral treatment was defined as the onset of local or systemic inflammation as a result of pathogenic bacteria. Results Bacterial infections occurred in 21 of the 430 (4.9%) patients during TVR-based triple therapy. Among these subjects, 71.4% (15 of 21) experienced bacterial infections during the initial eight weeks of treatment. Urinary tract infections were the most frequent infection, observed in 2.8% of cases (12 of 430). The rate of urinary tract infection among women (11 of 215, 5.1%) was significantly higher than that observed among men (1 of 215, 0.5%) (p<0.0001). According to a multivariable logistic regression analysis, the only significant independent predictor was the pretreatment serum albumin level (p=0.0008). Of the 21 patients who experienced bacterial infections, only one (4.8%) had to discontinue the treatment; however, the others were able to continue anti-viral treatment in combination with antibiotic treatment. Conclusion Clinicians should be concerned regarding the incidence of bacterial infections among patients treated with TVR-based triple therapy, especially those with a low serum albumin level.
UR - http://www.scopus.com/inward/record.url?scp=84926619364&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84926619364&partnerID=8YFLogxK
U2 - 10.2169/internalmedicine.54.3457
DO - 10.2169/internalmedicine.54.3457
M3 - Article
VL - 54
SP - 567
EP - 572
JO - Internal Medicine
JF - Internal Medicine
SN - 0918-2918
IS - 6
ER -